Impact of biologics and small molecules for inflammatory bowel disease on COVID ‐19‐related hospitalization and mortality: A systematic review and meta‐analysis

Article activity feed

1. Version published to 10.1002/jgh3.12728

   Mar 20, 2022
2. 

   ScreenIT

   Oct 28, 2021

   SciScore for 10.1101/2021.10.24.21265344: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	not detected.
   Sex as a biological variable	not detected.
   Randomization	In terms of types of studies, we included randomized, controlled trials, observational studies, and editorial were included.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Software and Algorithms
   Sentences	Resources
   Search Strategy: MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials databases were searched from December 1st, 2019, to September 1st, 2021, using predetermined search terms (Supplementary file table 1).	MEDLINE suggested: (MEDLINE, RRID:SCR_002185) Embase suggested: (EMBASE, RRID:SCR_001650) Cochrane Central Register of Controlled Trials suggested: (Cochrane Central Register of …

   SciScore for 10.1101/2021.10.24.21265344: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	not detected.
   Sex as a biological variable	not detected.
   Randomization	In terms of types of studies, we included randomized, controlled trials, observational studies, and editorial were included.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Software and Algorithms
   Sentences	Resources
   Search Strategy: MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials databases were searched from December 1st, 2019, to September 1st, 2021, using predetermined search terms (Supplementary file table 1).	MEDLINE suggested: (MEDLINE, RRID:SCR_002185) Embase suggested: (EMBASE, RRID:SCR_001650) Cochrane Central Register of Controlled Trials suggested: (Cochrane Central Register of Controlled Trials, RRID:SCR_006576)
   Furthermore, Google scholar was also searched for unindexed studies.	Google scholar suggested: (Google Scholar, RRID:SCR_008878)
   Statistical analysis was conducted using Review Manager (RevMan) version 5.3.5 (The Cochrane Collaboration).	RevMan suggested: (RevMan, RRID:SCR_003581) Cochrane Collaboration suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Inclusion of good quality studies with detailed extraction of data, and rigorous evaluation of study quality lend great credibility and strength to our systematic review and meta-analysis Our study limitations include the observational nature of included studies with risk of confounding and selection bias. Furthermore, patient level data were lacking, and insufficient data is available to stratify patients by different factors, including age, disease activity, and socio-economic assessments of the patients. Additional research is needed to ascertain which risk factors play significant roles in causing COVID-19 related hospitalization. Finally, the majority of patients included in our study were extracted from the SECURE-IBD database. One disadvantage of this database is that it may be subject to reporting bias, which means that physicians tend to document severe cases, while the milder cases may remain underreported. Additional research is needed to further evaluate causality between the use of biologic therapies and COVID-19 outcomes. In conclusion, Regarding COVID-19 related hospitalization in IBD, Anti-TNFs and ustekinumab were associated with favorable outcomes. In addition, vedolizumab and tofacitinib were not associated with COVID-19 related hospitalization.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04425538	Completed	A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (C…

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.10.24.21265344v1 on medRxiv

   Oct 26, 2021